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Background & aims: The assessment of body composition (BC) can be used to identify malnutrition in
patients with Crohn's disease (CD). The aim of this study was to evaluate the nutritional status of CD
patients by assessing BC, phase angle (PhA) and muscle strength. Differences in disease duration and
medications were also considered.
Methods: Consecutive adult CD patients aged 18e65 years were enrolled in this cross-sectional study.
Disease activity was clinically deﬁned by the Crohn's Disease Activity Index (CDAI) in the active and
quiescent phases. All participants underwent anthropometry, BC and handgrip-strength (HGS) mea-
surements; additionally, blood samples were taken. Data from CD patients were also compared with age-
, sex- and BMI-matched healthy people.
Results: A total of 140 CD patients with a mean age of 38.8 ± 13.9 years and a mean body weight of
64.9 ± 12 kg were recruited and compared to controls. The ﬁndings showed that all nutritional pa-
rameters, especially PhA and HGS, were lower in CD patients than in controls, and these parameters were
substantially impaired as disease activity increased. Active CD patients had a lower body weight and fat
mass than both the quiescent and control groups. PhA was negatively correlated with age (r ¼ 0.362;
p ¼ 0.000) and CDAI (r ¼ 0.135; p ¼ 0.001) but was positively associated with fat free mass (FFM)
(r ¼ 0.443; p ¼ 0.000) and HGS (r ¼ 0.539; p ¼ 0.000). Similarly, serum protein markers were lower in
the active CD group than in the quiescent group (p < 0.05). Disease duration and medications did not
signiﬁcantly affect nutritional status.
Conclusions: BIA-derived PhA is a valid indicator of nutritional status in CD patients, and its values
decreased with increasing disease activity. Additionally, small alterations in BC, such as low FFM, and
reduced HGS values can be considered markers of nutritional deﬁciency. Therefore, the assessment of BC
should be recommended in clinical practice for screening and monitoring the nutritional status of CD
patients.
© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Body Mass Index; BC, Body
ease Activity Index; CRP, C-
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Crohn's disease (CD) is a chronic inﬂammatory disorder
involving any part of the gastro-intestinal tract and is characterized
by a relapsing course [1]. Patients affected by CD have an increased
risk of malnutrition due to malabsorption, diarrhea, multiple in-
testinal resection, inadequate food intake, enhanced nutrient re-
quirements, anorexia, pain and vomiting [2]. Recently, the current
criteria for the diagnosis of malnutrition recommend the assess-
ment of body composition (BC) [3] since body mass index (BMI)under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nearly one-third of CD patients had altered body composition, with
reductions in both lean and fat mass, despite only 5% of them being
underweight according to BMI criteria [4].
Bioelectrical impedance analysis (BIA) is a portable, easy-to-use
and inexpensive method for estimating fat mass (FM) and fat-free
mass (FFM) in clinical settings [5]. Speciﬁcally, BIA measures
whole-body impedance, the opposition of the body to alternating
current consisting of two components: resistance (R) and reactance
(Xc). Themost clinically relevant impedance parameter is the phase
angle (PhA), an index of cell membrane integrity and vitality, which
provides crucial information on cellular health and soft tissue hy-
dration [6]. PhA, however, can be affected by several clinical con-
ditions, including inﬂammation, malnutrition, and prolonged
physical inactivity, resulting in its prominent reduction [7e10]. Low
PhA values are usually associated with impaired muscle function,
poor physical performance [5,11e13] and low survival [6,14].
Theoretically, PhA might be considered a nutritional indicator
since malnutrition is characterized by alterations in ﬂuid balance
and changes in cellular membrane integrity. As such, many studies
used PhA as a tool for predicting nutritional status as well as for
assessing clinical results and/or disease progression in different
clinical conditions [15e18]. To date, however, only a few studies
[19,20] have assessed impedance parameters to identify and
monitor nutritional risk in adults with CD, showing contrasting
results.
CD patients can be at risk of malnutrition evenwhen the disease
appears quiescent [21] since the degree of malnutrition is strongly
inﬂuenced by the activity, duration and extent of the disease and by
the inﬂammatory response. However, the widespread use of bio-
logic agents for CD treatment has allowed for an improved and
sustained control of mucosal inﬂammation as well as of symptoms
in a signiﬁcant proportion of patients [22e26], which is expected to
positively affect nutritional status.
Thus, the aims of the present study were 1) to evaluate body
composition, PhA (total and segmental) and muscle strength as
indicators of nutritional status in CD patients; 2) to verify the
impact of clinical disease activity on nutritional and functional
status; and 3) to assess whether disease duration and drug treat-
ments could inﬂuence body composition and PhA.2. Materials and methods
2.1. Design and study population
This cross-sectional study focused on nutritional status evalu-
ation in patients with CD by including BIA parameters, such as PhA,
and muscle strength. Adult patients with a diagnosis of CD ac-
cording to the European Crohn's and Colitis Organization (ECCO)
guidelines, were consecutively recruited from July 2016 until March
2018 at the Department of Clinical Medicine and Surgery, Federico
II University Hospital, Naples (Italy). The inclusion criteria were a
diagnosis of CD and an age between 18 and 65 years. The exclusion
criteria were as follows: use of corticosteroids in the last 3 months;
history of acute or chronic liver or kidney disease; current enteral
(i.e., tube feeding) or parenteral nutrition, presence of ﬁstulae,
ileostomy or colostomy; presence of extensive small bowel re-
sections (residual small bowel < 2 m); pregnancy or lactation;
unstable body weight in the last month; and unable or unwilling to
give informed consent.
Additionally, data from age- sex- and BMI-matched healthy
people (n ¼ 83) were randomly selected from our database
(Caucasian adults, aged between 18 and 75 years) to serve as a
control group.Please cite this article as: Ciofﬁ I et al., Assessment of bioelectrical phas
disease: A cross sectional study, Clinical Nutrition, https://doi.org/10.1016All measurements were performed early in the morning after a
fasting period of 8e10 h according to standardized conditions, i.e.,
abstaining from alcohol and vigorous physical activity for 24 h prior
to the assessment. Clinically, disease activity was deﬁned by the
Crohn's Disease Activity Index (CDAI), classifying patients in the
active and quiescent phases (150 and <150, respectively). De-
mographic data, disease duration, smoking habits, previous sur-
gery, drug treatment and location and disease behavior (Montreal
classiﬁcation) were also collected. The study was conducted ac-
cording to the Declaration of Helsinki and received the approval of
the Federico II Ethical Committee (Protocol's number: 102/16) and
was registered at clinicaltrials.gov as NCT03054935. All participants
provided written informed consent prior to enrolment.
2.2. Anthropometry and bioelectrical impedance analysis
Body weight and height were measured to the nearest 0.1 kg
and 0.5 cm, respectively, and were taken while the subjects wore
light clothes and no shoes using a platform beam scale with a built-
in stadiometer (Seca 709; Seca, Hamburg Germany). BMI was
calculated as body weight expressed in kilograms divided by
squared height reported in meters.
BIA [27] was performed at 50 kHz (Human In Plus II, DS Medica,
Milan, Italy) with a constant room temperature of 22e25 C.
Measurements were carried out on the nondominant side of the
body, in the postabsorptive state, after voiding and with the subject
in the supine position for 20 min. The BIA variables considered
were R and Xc, while PhAwas calculated as arc tangent Xc/R x 180/
p and expressed in degrees. For the segmental BIA exam, the length
of each segment was measured, and the electrodes were properly
positioned to obtain R and Xc values for each of the following
segments: arm and leg. This evaluationwas conducted according to
the Organ method [28]. Finally, FFM and FM were estimated by
using the predictive equations developed by Kushner [29].
2.3. Muscle strength measurement
Handgrip strength (HGS) measures the ability of the hand
muscles to generate tension (force) through a handshake by using a
dynamometer (JAMAR, Roylan, UK). Subjects were placed standing
with arms outstretched parallel to the trunk and then held the
dynamometer and applied maximum strength with each hand
without support. The measurement was repeated three times
alternately on both sides (dominant and nondominant hand) with
1 min apart to avoid fatigue; then, the mean value was recorded in
kilograms (kg) [30].
2.4. Biochemical indicators
Blood samples were taken to evaluate several biomarkers
involved in nutritional status, such as albumin (g/dl), hemoglobin
(Hb) (g/dl), total cholesterol (mg/dl), total lymphocytes (103/ml),
prealbumin (g/L), pseudocholinesterase (UI), alpha-2 fraction (%),
C-reactive protein (CRP) (mg/L), ﬁbrinogen (mg/dl), total protein (g/
dl), transferrin (g/dl) and ferritin (ng/dl). All determinations were
performed at the centralized laboratory of Federico II University
Hospital following standardized techniques.
2.5. Statistical analysis
Data are presented as the mean ± standard deviation [SD], un-
less otherwise speciﬁed. The KolmogoroveSmirnov Test and the
ShapiroeWilk Test were used as tests of normality to examine
whether variables were normally distributed. Data were compared
between the CDAI groups using an unpaired t-test, while data weree angle as a predictor of nutritional status in patients with Crohn's
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treatments by using one-way ANOVA with Tukey post hoc com-
parisons. Linear correlation was applied to evaluate associations
between variables. Statistical analysis was performed using SPSS
ver. 22.0 (IBM Corporation, Inc. Chicago, IL, USA). A p value < 0.05
was considered signiﬁcant.
3. Results
One hundred forty-eight CD patients were recruited for this
study. Six were excluded for not fulﬁlling the inclusion criteria, and
2 were excluded for taking corticosteroids. Therefore, a total of 140
CD patients (82 males and 58 females) were ﬁnally included in the
analysis, showing a mean age of 38.8 ± 13.9 years, an average
weight of 64.9 ± 12 kg and a BMI of 23.2 ± 3.72 kg/m2. Based on the
CDAI score, 78 patients were in the quiescent phase (CDAI< 150),
while 62 showed mild to moderate disease activity
(150 > CDAI < 450). All demographic and clinical characteristics of
patients are shown in Table 1. Brieﬂy, most of the participants
(n¼ 102) had a normal weight (73%), 9 (6.4%), mainly women, were
underweight and 29 (20%) were overweight/obese according to
BMI criteria. The overall disease duration ranged between 0.5 and
36 years, with an average time of 9 years in both sexes, while 53% of
the entire sample underwent previous surgery due to CD.
Regarding smoking status, 26 patients were smokers, 22 were ex-
smokers and 91 had never smoked. Based on the Montreal classi-
ﬁcation, CD was mainly diagnosed at an age between 17 and 40
years (66%), located in the ileume colon (57%) and characterized by
a stricturing phenotype (54%). Finally, regarding the use ofTable 1
Demographic and clinical characteristics of CD patients.
Total Men Women
N, (%) 140 (100) 82 (58.6) 58 (41.4)
BMI, n (%)
<18.5 kg/m2 9 (6.4) 1 (1.2) 8 (13.8)
18.5e24.9 kg/m2 102 (72.9) 66 (80.5) 36 (62.1)
25e29.9 kg/m2 21 (15) 12 (14.6) 9 (15.5)
>30 kg/m2 8 (5.7) 3 (3.7) 5 (8.6)
Previous surgery, n (%) 74 (52.9) 41 (50.0) 33 (56.9)
Mean duration (years), y [range] 8.80 [0.5e36] 9.01 [1e30] 8.52 [0.5e36]
Currently smoking habits n (%)
Yes 26 (18.6) 13 (15.9) 13 (22.4)
No 91 (65.0) 57 (69.5) 35 (60.3)
Ex-smoker 22 (15.8) 12 (14.6) 10 (17.2)
Clinical activity, n (%)
CDAI < 150 78 (55.7) 50 (61) 28 (48.3)
>150 CDAI < 450 62 (44.3) 32 (39) 30 (51.7)
Montreal age at diagnosis, n (%)
A1: <16 y 26 (18.6) 17 (20.7) 9 (15.5)
A2: 17e40 y 93 (66.4) 53 (64.6) 40 (69.0)
A3: >40 y 21 (15.0) 12 (14.6) 9 (15.5)
Montreal disease location, n (%)
L1: Ileum 46 (32.9) 28 (34.1) 18 (31.0)
L2: Colon 11 (7.9) 10 (12.2) 1 (1.7)
L3: Ileum and colon 80 (57.1) 42 (51.2) 38 (65.5)
L4: Upper GI tract 3 (2.1) 2 (2.4) 1 (1.7)
Montreal disease behaviour, n (%)
B1: Inﬂammatory 37 (26.4) 27 (32.9) 10 (17.2)
B2: Stricturing 76 (54.3) 43 (52.4) 33 (56.9)
B3: Penetrating 27 (19.3) 12 (14.6) 15 (25.9)
Perianal disease, n (%) 30 (21.4) 17 (20.7) 13 (22.4)
Medications, n (%)
None 43 (30.7) 23 (28.0) 20 (34.5)
5-ASA 17 (12.1) 14 (17.0) 10 (17.2)
IMMs 24 (17.1) 9 (17.1) 8 (13.8)
Biologics 56 (40.0) 36 (43.9) 20 (34.5)
Body Mass Index (BMI); Crohn Disease Activity Index (CDAI); years (y); amino sal-
icylic acid (ASA); Immunosuppressives (IMMs).
Please cite this article as: Ciofﬁ I et al., Assessment of bioelectrical phas
disease: A cross sectional study, Clinical Nutrition, https://doi.org/10.1016medications, we found that biologic agents were used in 40% of
patients, followed by immunosuppressives and mesalazine treat-
ments (17% and 12%, respectively). Surprisingly, almost 31% of pa-
tients were not being treated at the time of the study visit due to
the screening phase before starting biologic therapy.3.1. Body composition, phase angle and muscle strength
As mentioned before, a group of healthy age-, sex- and BMI-
matched subjects (n ¼ 83; 45 males and 38 females) were
selected. Age, body weight, BMI, all BIA variables, including total-
and segmental PhA values and muscle strength are shown for CD
patients and controls in Table 2. Overall, the nutritional status of CD
patients differed from that of the control group. We found that
body weight, BMI, FFM and HGS as well as total and arm-PhA were
signiﬁcantly lower in all CD patients than in controls. A subgroup
analysis was performed by splitting CD patients according to CDAI.
Our ﬁndings showed that patients in the active group had a lower
bodyweight, FM, and total and leg-PhA than both the quiescent and
control groups. However, BMI, FFM and arm-PhA were different
only between the active CD group and the controls. Finally, HGS did
not change between the CDAI groups but signiﬁcantly differed
compared to that of the controls.
Next, we performed the statistical analyses taking sex differ-
ences into account, as presented in Table 3. Overall, we observed
reduced values for body weight, BMI, FFM, FM (in kg), HGS and
arm-PhA in male CD patients compared with the same parameters
in controls. In females, we found lower FFM than in the control
group, although both showed a similar BMI; furthermore, HGS as
well as total- and arm-PhA values are reduced. After stratifying by
CDAI, we showed that both males and females in the active group
had decreased values of FM (expressed both as kg and percentage)
and total and leg-PhA than those in the quiescent group. Addi-
tionally, active females had a lower body weight than those in the
quiescent phase. After comparing the three groups, we observed
that FFM and HGS were signiﬁcantly lower in CD patients than in
controls, independent of sex and CDAI. However, both FM and leg-
PhA values were reduced in both male and female CD patients for
the active group only.3.2. Correlation coefﬁcients between PhA, age, body composition
and HGS
Pearson correlation coefﬁcients for the association of total PhA
with individual characteristics and all BIA variables in CD patients
are shown in Table 4. We found that total PhA was negatively
correlated with age (r ¼ 0.362; p ¼ 0.000), CDAI (r ¼ 0.315;
p ¼ 0.000) and fat percentage (r ¼ 0.206; p ¼ 0.01), whereas it
was positively associated with body weight (r ¼ 0.353; p ¼ 0.000),
FFM (r ¼ 0.443; p ¼ 0.000) and HGS (r ¼ 0.539; p ¼ 0.000). Similar
correlations were found in both CDAI groups, except FM (%) was not
signiﬁcantly associated with PhA in the active group.
For further analysis, correlations were controlled for age and
sex. Again, our ﬁndings showed that total PhA was inversely
correlated with CDAI (r ¼ 0.267; p ¼ 0.002) and positively asso-
ciated with body weight (r ¼ 0.169; p ¼ 0.04), BMI (r ¼ 0.240;
p ¼ 0.005), FM expressed in kg (r ¼ 0.212; p ¼ 0.012) and per-
centage (r¼ 0.214; p¼ 0.012) and HGS (r¼ 0.153; p¼ 0.05) but not
with FFM (r ¼ 0.029; p ¼ 0.765).
Finally, HGS was correlated with segmental PhAvalues, showing
a positive association with both arm- (r ¼ 0.626; p ¼ 0.000) and
leg-PhA (r ¼ 0.318; p ¼ 0.000) values, as presented in Fig. 1, high-
lighting a stronger correlation of arm-PhA than that of the leg
values.e angle as a predictor of nutritional status in patients with Crohn's
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Table 2
Age, BMI, body composition, handgrip strength and phase angle measurements in all CD patients and controls.
Active (n ¼ 62) Quiescent (n ¼ 78) pa All (n ¼ 140) Controls (n ¼ 83) pb pc
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age, years 39.6 ± 14.2 38.2 ± 13.8 0.805 38.8 ± 14.0 37.5 ± 11.0 0.458 0.624
Weight, kg 61.9 ± 10.8 67.3 ± 12.5 0.034 64.9 ± 12.0 70.5 ± 13.9 0.002 0.000x
BMI, kg/mb 22.5 ± 3.17 23.7 ± 4.04 0.106 23.2 ± 3.72 24.2 ± 3.5 0.028 0.012x
FFM, kg 48.2 ± 10.8 50.0 ± 9.78 0.591 49.2 ± 10.2 53 ± 12.1 0.013 0.028x
FM kg 13.7 ± 6.67 17.3 ± 8.79 0.022 15.7 ± 8.10 17.5 ± 7.64 0.100 0.008x
FM, % 22.3 ± 10.2 25.2 ± 10.4 0.186 23.9 ± 10.4 24.8 ± 8.78 0.489 0.170
HGS, kg 27.6 ± 10.4 28.7 ± 10.1 0.769 28.2 ± 10.2 33.8 ± 7.97 0.000 0.000z
Total PhA, () 6.07 ± 0.92 6.58 ± 0.90 0.002 6.35 ± 0.94 6.81 ± 0.79 0.000 0.000x
Arms PhA, () 5.46 ± 1.03 4.87 ± 0.95 0.159 4.73 ± 0.99 5.30 ± 1.02 0.000 0.000x
Legs PhA, () 7.18 ± 1.11 7.95 ± 1.05 0.000 7.61 ± 1.14 7.75 ± 1.34 0.433 0.001x
CDAI: Chron's Disease Activity Index; FFM: fat free mass; FM: fat mass; HGS: handgrip strength, PhA: phase angle.
a Un-paired T test between active vs. quiescent.
b Un-paired T test between All vs. controls.
c ANOVA test among active, quiescent and controls with signiﬁcant values between: (x) active vs. controls; (z) active and quiescent vs. controls.
Table 3
Age, BMI, body composition, phase angle and handgrip strength in all CD patients and controls according to sex.
Active (M ¼ 32; W ¼ 30) Quiescent (M ¼ 50; W ¼ 28) pa All (M ¼ 82; W ¼ 58) Controls (M ¼ 45; W ¼ 38) pb pc
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age, years
Males 40.4 ± 13.7 36.6 ± 13.7 0.215 38.1 ± 13.8 38.2 ± 12.6 0.748 0.241
Females 38.6 ± 15 41.1 ± 14 0.524 39.8 ± 14.4 36.8 ± 9.01 0.128 0.438
Weight, kg
Males 67.9 ± 8.5 70.9 ± 11.1 0.204 69.7 ± 10.2 78.4 ± 12.7 0.000 0.000z
Females 55.4 ± 9.25 60.8 ± 12.3 0.051 58.0 ± 11.1 60.9 ± 7.68 0.155 0.042x
BMI, kg/mb
Males 23.1 ± 2.5 23.7 ± 3.6 0.363 23.5 ± 3.2 25.3 ± 3.78 0.005 0.014x
Females 21.9 ± 3.7 23.7 ± 4.7 0.989 22.7 ± 4.3 23.1 ± 2.7 0.682 0.149
FFM, kg
Males 56.3 ± 6.6 55.8 ± 6.4 0.719 56.0 ± 6.5 61.9 ± 8.3 0.000 0.000z
Females 39.5 ± 6.7 39.6 ± 4.9 0.919 39.6 ± 5.9 42.5 ± 5.3 0.014 0.051z
FM kg
Males 11.6 ± 6.2 15.1 ± 7.9 0.038 13.7 ± 7.4 16.5 ± 8.7 0.047 0.026x
Females 15.9 ± 6.6 21.2 ± 9.0 0.015 18.5 ± 8.2 18.4 ± 5.9 0.989 0.025x
FM, %
Males 16.7 ± 7.8 20.4 ± 8.4 0.046 18.9 ± 8.4 20.3 ± 8.1 0.319 0.079
Females 28.2 ± 9.2 33.7 ± 7.8 0.019 30.9 ± 8.9 29.9 ± 6.6 0.600 0.030x
HGS, kg
Males 35.7 ± 7.1 34.7 ± 7.4 0.552 35.1 ± 7.2 39.9 ± 4.4 0.000 0.001z
Females 23.7 ± 6.0 23.2 ± 5.3 0.440 18.7 ± 4.6 26.7 ± 4.8 0.000 0.000z
Total PhA, ()
Males 6.58 ± 0.92 6.95 ± 0.84 0.048 6.80 ± 0.89 6.88 ± 0.73 0.065 0.033x
Females 5.52 ± 0.54 5.93 ± 0.60 0.008 5.72 ± 0.60 6.28 ± 0.45 0.000 0.000z
Arms PhA, ()
Males 5.23 ± 0.80 5.32 ± 0.82 0.643 5.29 ± 0.81 5.61 ± 0.86 0.037 0.104
Females 3.81 ± 0.69 4.07 ± 0.57 0.123 3.94 ± 0.64 4.77 ± 1.01 0.000 0.000z
Legs PhA, ()
Males 7.47 ± 1.25 8.23 ± 1.09 0.005 7.93 ± 1.21 8.26 ± 1.17 0.148 0.006x
Females 6.86 ± 0.84 7.46 ± 0.76 0.007 7.16 ± 0.85 7.14 ± 1.29 0.959 0.049x
CDAI: Chron's Disease Activity Index; FFM: fat free mass; FM: fat mass; HGS: handgrip strength, PhA: phase angle.
a Un-paired T test between active vs. quiescent.
b Un-paired T test between all vs. controls.
c ANOVA test among active, quiescent and controls with signiﬁcant values between:(x) active vs. controls; (z) active and quiescent vs. control.
I. Ciofﬁ et al. / Clinical Nutrition xxx (xxxx) xxx43.3. Biochemical markers
Both nutritional and inﬂammatory markers were assessed in
all CD patients, as presented in Table 5. The data showed that
Hb, albumin, prealbumin, total protein and pseudocholines-
terase were lower in active CD patients than in the quiescent
group (p < 0.05), while the alpha-2 fraction, ﬁbrinogen and CRP
were higher (p < 0.05). Additionally, those variables were
correlated with total PhA, observing a direct association with Hb
(r ¼ 0.299; p ¼ 0.000), albumin (r ¼ 0.389; p ¼ 0.000), pre-
albumin (r ¼ 0.195; p ¼ 0.023) and total protein (r ¼ 0.202;Please cite this article as: Ciofﬁ I et al., Assessment of bioelectrical phas
disease: A cross sectional study, Clinical Nutrition, https://doi.org/10.1016p ¼ 0.01). An inverse correlation with PhA was found for the
alfa-2 fraction (r ¼ 0.192; p ¼ 0.022) and ﬁbrinogen
(r ¼ 0.246; p ¼ 0.003).
3.4. Disease duration, location and behavior
Among the 140 patients, 92 had a disease duration >5 years and
44 had a disease duration between 1 and 5 years, while 4 patients
had a recent diagnosis (<1 year). Comparing the 2 largest groups,
no difference was found in FFM or PhA values, even when the
analysis was stratiﬁed by sex.e angle as a predictor of nutritional status in patients with Crohn's
/j.clnu.2019.06.023
Table 4
Pearson's correlation coefﬁcients between total phase angle, individual character-
istics and BIA parameters.
Active (n ¼ 62) Quiescent (n ¼ 78) All (n ¼ 140)
Age, years 0.254* 0.453** 0.362**
CDAI 0.211 0.123 0.135**
Weight, kg 0.356** 0.290** 0.353**
BMI, kg/m2 0.138 0.087 0.146
FFM, kg 0.383** 0.486** 0.443**
FM kg 0.057 0.129 0.035
FM, % 0.196 0.304** 0.296*
HGS, kg 0.588** 0.514** 0.539**
CDAI: Chron's Disease Activity Index; FFM: fat free mass; FM: fat mass; HGS:
handgrip strength.
*p < 0.05; **p < 0.001.
I. Ciofﬁ et al. / Clinical Nutrition xxx (xxxx) xxx 5With regard to disease location (Montreal classiﬁcation), we
observed that the disease was mainly located in the ileum-colon
(L3, n ¼ 80), followed by the ileum (L1, n ¼ 46). By analyzing pa-
tients according to disease location (L1 vs. L3), we did not ﬁnd
differences between patients, except for FFM, which was lower in
males in the L3 group than in those in the L1 group (L1:
FFM¼ 58.4 ± 5.5 kg vs. L3: FFM¼ 53.9 ± 6.6 kg; p¼ 0.003). Disease
behavior did not inﬂuence any of the nutritional or functional
variables considered.a
b
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Fig. 1. Correlation between arms (a) and legs (b) PhA values with mean HGS. Linear
correlation was applied for assessing the relation between both arms (a) and legs (b)
PhA values with mean HGS in all CD patients, taking CDAI differences into account.
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Finally, CD patients were split into three groups according to
therapies as follows: 1) biologic (inﬂiximab n ¼ 17, adalimumab
n ¼ 32, and vedolizumab n ¼ 7), 2) conventional
(immunosuppressives þ mesalazine) and 3) no therapy. ANOVA
post hoc analysis did not reveal any signiﬁcant difference in PhA, BC
or muscle strength between treatment groups (Table 6); however,
both total- and segmental-PhA (arms and legs) were higher, albeit
not signiﬁcantly, in the biologic group. Indeed, compared to con-
trols, total PhAwas signiﬁcantly lower in both the conventional and
no therapy groups, but not for patients on biologic treatment. All CD
groups showed lower arm-PhA and HGS values than the control
group, while only patients not undergoing therapy had a lower
body weight.
4. Discussion
This cross-sectional study aimed to investigate the nutritional
status of patients with CD by assessing body composition, phase
angle and muscle strength. Our ﬁndings showed that BIA-derived
PhA is a valid indicator of nutritional status in CD patients and
that its values decreased with increasing disease activity. The re-
sults showed that patients in the active phase had a lower FM than
those who were clinically quiescent, while all of them, unrelated to
CDAI and sex, had signiﬁcantly lower lean mass and muscle
strength than the age-, sex- and BMI-matched healthy controls.
Finally, drug treatments did not inﬂuence any of the nutritional
variables considered, although PhA was slightly better in patients
receiving biologic therapy.
Patients with CD usually develop secondary malnutrition. The
most widely used parameter to assess nutritional status is BMI, but
taken alone, BMI is inaccurate. In fact, even with an apparently
normal BMI, abnormalities in both FFM and FM distribution can be
observed [31]. Overall, it has been recognized that altered BC
among CD patients may negatively impact the course of the illness,
response to therapies and surgery outcomes [4]. Thus, clinical
awareness of BC evaluation and appropriate nutritional manage-
mentmay lead to improved outcomes for patients with this chronic
disease.
The results of the BC evaluation presented by previous studies
suggested that CD patients are affected by alterations in FM and
FFM, which may not be detected or easily recognized by routine
clinical assessment [4]. Generally, they tend to develop a relative
reduction in lean mass and an increase in adiposity over time, but
data are still contrasting due to differences in study design and
characteristics of the included patients [32e34]. Based on BMI
criteria, we found that only 9 out of 140 CD patients were under-
weight and therefore at increased risk of malnutrition. However,
after performing BC analysis, we observed that all active CD pa-
tients had lower FM and body weight than the quiescent CD pa-
tients, but no difference was found in FFM, even when data were
separated by sex. Similar results were reported by Yadav et al. [33],
who showed a progressive, though not statistically signiﬁcant,
decline in BMI and FM (expressed as absolute and percentage
values) with an increase in disease severity, but there was no effect
on FFM. Still, the results from Back et al. [34] showed lower BMI and
mid-arm circumference in active CD patients than quiescent
patients.
Compared to controls, we found that FFM was signiﬁcantly
lower in both CDAI groups, while FM decreased in the active group
only. In detail, our female patients had lower FFM values than
controls, even though their BMI did not differ. Similar results were
observed by Weich et al. [35] in adolescent CD patients and by
Filippi et al. [36], who reported low FM in quiescent adult CDe angle as a predictor of nutritional status in patients with Crohn's
/j.clnu.2019.06.023
Table 5
Biochemical parameters in all CD patients as well as according to disease activity.
Active (n ¼ 62) Quiescent (n ¼ 78) All (n ¼ 140)
Mean ± SD Mean ± SD Mean ± SD
Hemoglobin, g/dl 12.8 ± 1.44** 13.9 ± 1.63 13.4 ± 1.63
Lymphocyte, 103/ml 1.74 ± 0.66 1.61 ± 0.58 1.67 ± 0.62
Albumin, g/dl 3.90 ± 0.55** 4.29 ± 0.45 4.12 ± 0.53
Pre-albumin, g/L 0.23 ± 0.08* 0.33 ± 0.34 0.28 ± 0.26
Total protein, g/dl 6.66 ± 0.85** 7.13 ± 0.68 6.92 ± 0.79
Pseudo-cholinesterase, UI 8346 ± 2574* 9281 ± 2010 8868 ± 2796
alfa2 Fraction, % 11.3 ± 2.38** 10.0 ± 2.17 10.6 ± 2.35
Transferrin, g/L 2.48 ± 0.61 2.59 ± 0.49 2.54 ± 0.55
Total Cholesterol, mg/dl 148 ± 41.3 157 ± 44.2 153 ± 43
Fibrinogen, mg/dl 402 ± 92.0** 347 ± 84.9 372 ± 92.0
Ferritin (median, IQR), ng/ml 41 (74) 63 (82) 53.5 (80)
CRP (median, IQR), mg/l 5 (9.8) * 2.0 (6.1) 3.15 (8.0)
CRP: C-reactive protein, Interquartile Range (IQR); *p < 0.05; **p < 0.001.
Table 6
Age, BMI, body composition, handgrip strength and phase angle according to treatment.
Biologics (n ¼ 56) Conventional (n ¼ 40) No therapy (n ¼ 43) Controls (n ¼ 83) pa
Age, years 38.3 ± 13.6 40.0 ± 14.6 38.3 ± 14.1 37.5 ± 11.0 0.799
Weight, kg 65.0 ± 10.9 66.1 ± 13.9 64.1 ± 11.7 70.5 ± 13.9 0.016*
BMI, kg/m2 22.8 ± 3.25 23.7 ± 4.86 23.1 ± 3.02 24.2 ± 3.5 0.105
FFM, kg 49.5 ± 8.83 49.7 ± 10.3 48.2 ± 11.9 53 ± 12.1 0.085
FAT, kg 15.1 ± 7.26 16.4 ± 9.59 15.9 ± 7.75 17.5 ± 7.64 0.338
FAT, % 23.0 ± 9.39 24.1 ± 10.7 24.9 ± 11.4 24.8 ± 8.78 0.692
HGS, kg 28.9 ± 9.19 27.1 ± 10.2 28.3 ± 11.7 33.8 ± 7.97 0.000
Total PhA, () 6.50 ± 0.89 6.23 ± 0.99 6.28 ± 0.87 6.81 ± 0.79 0.001^
Arms PhA, () 4.85 ± 1.00 4.62 ± 0.17 4.69 ± 0.91 5.30 ± 1.02 0.001
Legs PhA, () 7.74 ± 1.34 7.57 ± 1.13 7.51 ± 1.28 7.75 ± 1.34 0.663
BMI: body mass index, FFM: fat free mass; FM: fat mass; HGS: handgrip strength, PhA: phase angle.
a ANOVA test showing with signiﬁcant values between: (*) No therapy vs. controls; () All groups vs. controls and (^ ) Conventional and No therapy vs. controls.
I. Ciofﬁ et al. / Clinical Nutrition xxx (xxxx) xxx6patients, while Valentini et al. [37] did not ﬁnd any differences in BC
between healthy individuals and CD patients.
A variety of methods can be employed to measure BC, such as
dual energy X-ray absorptiometry (DXA), dilution techniques, BIA,
air-displacement plethysmography (ADP) or magnetic resonance
imaging (MRI), but none of them are error free [38]. Generally, the
more advanced techniques are less accessible, time-consuming and
more costly and as a result are not always feasible in clinical
practices. Moreover, some tools, such as the isotopes dilution
technique, BIA or ADP, can result in lower accuracy if used in
different clinical conditions because they require the assumption of
a constant hydration state [38].
Nevertheless, from BIA, we can directly measure PhA, an index of
soft tissue mass quality, which has gained great popularity in nutri-
tional assessment and monitoring in recent years. Indeed, a higher
PhA reﬂects higher cellularity, cell membrane integrity and cell
function, whereas reduced PhA reﬂects lower integrity and quality
cell mass and is associatedwith unfavorable disease progression and
poor prognosis. Indeed, disease-related malnutrition as well as
mortality rate [14] have been shown to be associated with altered
electric properties of the tissues that are detectable by BIA [39].
Generally, PhA ranges between 5 and 7 in healthy subjects
[40,41], and in athletes, it might reach 8.5 [42], but several factors,
such as diseases, inﬂammation, infection, etc. could affect those
values. In this study, the mean PhA value was within the normal
range; however, we observed a small decline with the increase of
disease activity in both sexes, resulting in levels lower than those in
healthy subjects.
Back et al. [34] did not ﬁnd any differences in PhA values be-
tween active and quiescent CD patients (p ¼ 0.75), while Wiech
et al. [35] showed that PhA was reduced in adolescent CD patients
compared to the values of the controls. Interestingly, we found thatPlease cite this article as: Ciofﬁ I et al., Assessment of bioelectrical phas
disease: A cross sectional study, Clinical Nutrition, https://doi.org/10.1016PhA was inversely correlated with CDAI, age and FM, while it was
positively associated with FFM and HGS, which was in accordance
with previous results [5]. However, by controlling for age and sex,
we found that PhA was still signiﬁcantly correlated with body
weight, BMI, FM, HGS and CDAI but not with FFM. Although PhA
can reveal both changes in the amount and quality of soft tissue
mass, it is not strictly associated with FFM values, especially in
disease conditions. Indeed, BIA results are population-speciﬁc and
mostly dependent on the prediction equation used to estimate FFM
and FM. As previously reported in a healthy population, the main
determinants of PhAvalues are sex and age [40,41]. Interestingly, by
performing a multivariate linear regression analysis in this sample,
we conﬁrmed the predictive role of sex and age in PhA values and
identiﬁed CDAI as an additional predictor. Precisely, regression
coefﬁcients were negative for age and CDAI, implying a decrease in
PhA with aging as well as with stronger disease activity, while it
was positive for sex, as previously shown [40,41].
To our knowledge, this is the ﬁrst study to assess PhA in different
body compartments, such as arms and legs. Segmental PhA data
showed that leg-PhA signiﬁcantly differed between the active and
quiescent groups, resulting in higher sensitivity than that of arm-
PhA in detecting changes between intra- and extracellular water.
Similar results were also reported by a previous study performed by
our group in cyclists, showing that leg-PhAwas correlated strongly
with changes in water distribution [43].
PhA is also associated with muscle functionality [44]. The hand-
grip strength measure is a simple tool that may be easily performed
in the clinical setting and is known to correlate well with overall
strength [45]. In our patients, we found that HGS was signiﬁcantly
lower than in controls, but therewas no difference between theCDAI
groups. Although themeanHGS observed in CDpatients appeared to
be normal, 41% of patients had HGS values below the cut-off pointse angle as a predictor of nutritional status in patients with Crohn's
/j.clnu.2019.06.023
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literature, Lu et al. [47] observed that HGS was lower in both males
and females with CD than in controls (p< 0.001); however, HGSwas
also signiﬁcantly higher in male CD patients with inactive disease
than in those with active disease (p < 0.05), as we found.
From a biochemical point of view, small differences in nutritional
and inﬂammatory markers emerged between active and quiescent
CD groups, contributing to the evaluation of nutritional status in
these patients. As expected, active CD patients had higher levels of
ﬁbrinogen, CRP and alpha-2 fraction at the protein electrophoresis
than the quiescent group, while albumin, prealbumin, total protein,
pseudocholinesterase and HB concentrations were reduced. Previ-
ous studies [34,48] showed that HB was lower in active CD patients
than in quiescent patients, whereas albumin, CRP and total protein
did not differ. Interestingly, all serum protein markers, such as al-
bumin, prealbumin and total protein, were directly correlated with
PhA, while ﬁbrinogen and CRP were inversely associated. Therefore,
these data highlighted that low protein markers and high inﬂam-
matory status can impair PhA values.
Finally, we analyzed the possible effect of drugs, especially bio-
logic therapy, on nutritional parameters since current data are still
unclear. Emerenziani et al. [19] reported increased PhA values in 23
clinical remission patients on inﬂiximab therapy compared to the
values of those on conventional therapy. In addition, they also
showed that in 12 active CD patients, following the induction pro-
tocol with inﬂiximab, FFM increased, albeit not signiﬁcantly, and
PhAnormalized. However, Santos et al. [20] showed that PhAdid not
improve after 24 weeks of inﬂiximab therapy in 23 CD patients
(p ¼ 0.53), and some differences were observed in BC, with a sub-
stantial increase in FM compared to FFM. Our ﬁndings did not show
any signiﬁcant differences between CD patients, although both total
and segmental PhA were slightly higher, albeit not signiﬁcantly, in
those on biologic therapy compared to the values of patients on
conventional therapy or no therapy. It should be speciﬁed, however,
that among patients on biologic therapy, approximately 40% started
therapy less than 3 months prior; nevertheless, no differences were
observed when they were removed from the analysis.
Our studyhad some limitations. AlthoughBIA is avalid and reliable
tool for BC analysis in clinical practice, it can be inﬂuenced by the state
of hydration, which can often result in modiﬁcations in the results of
CD patients due to diarrhea and malabsorption. Nevertheless, PhA,
which does not strictly require algorithm-inherent errors or assump-
tions such as constant tissue hydration [5], could be useful for
screening and monitoring the nutritional status of these patients.
Additionally, the studydesignadopted (cross-sectional) and the lackof
physical activity data can be considered further limitations.
In conclusion, PhA is a valid tool to assess nutritional status in
CD patients, as supported by nutritional biomarker evaluation, and
its values decreased with increasing disease activity. Although we
included CD patients with mild to moderate disease activity, we
observed reduced muscle strength in patients of both sexes
compared to that of controls, and small alterations in BC can be
considered a marker of nutritional deﬁciency. Therefore, the
assessment of BC, speciﬁcally of BIA-derived PhA, should be rec-
ommended in clinical practice for screening and monitoring the
nutritional status of CD patients.
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